Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRAX Stock Forecast 2026-2027
$314.56
Current Price
$8.77B
Market Cap
Buy 16
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to PRAX Price Targets
+281.8%
To High Target of $1,201.00
+78.8%
To Median Target of $562.50
-48.5%
To Low Target of $162.00
PRAX Price Momentum
-2.9%
1 Week Change
+18.0%
1 Month Change
+486.9%
1 Year Change
+6.7%
Year-to-Date Change
-14.2%
From 52W High of $366.52
+745.8%
From 52W Low of $37.19
📊 TOP ANALYST CALLS
Did PRAX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Praxis is one of their latest high-conviction picks.
Latest PRAX Stock Price Targets & Analyst Predictions
Based on our analysis of 9 Wall Street analysts, PRAX has a bullish consensus with a median price target of $562.50 (ranging from $162.00 to $1,201.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $314.56, the median forecast implies a 78.8% upside. This outlook is supported by 16 Buy, 1 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRAX Analyst Ratings
16
Buy
1
Hold
1
Sell
PRAX Price Target Range
Low
$162.00
Average
$562.50
High
$1,201.00
Current: $314.56
Latest PRAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 29, 2026 | Needham | Buy | Maintains | $N/A | |
| Jun 18, 2026 | RBC Capital | Outperform | Initiates | $N/A | |
| Jun 2, 2026 | Oppenheimer | Outperform | Maintains | $N/A | |
| Jun 2, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| Jun 2, 2026 | Deutsche Bank | Buy | Maintains | $N/A | |
| Jun 2, 2026 | Wedbush | Underperform | Maintains | $N/A | |
| Jun 2, 2026 | Baird | Outperform | Maintains | $N/A | |
| Jun 2, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jun 2, 2026 | BTIG | Buy | Maintains | $N/A | |
| May 26, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 20, 2026 | BTIG | Buy | Reiterates | $N/A | |
| May 13, 2026 | Truist Securities | Buy | Maintains | $N/A | |
| May 8, 2026 | Wedbush | Underperform | Maintains | $N/A | |
| May 8, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 14, 2026 | Needham | Buy | Reiterates | $N/A | |
| Apr 7, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 6, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Feb 24, 2026 | Wolfe Research | Outperform | Initiates | $N/A | |
| Feb 20, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Feb 20, 2026 | Baird | Outperform | Maintains | $N/A |
Praxis Precision Medicines Inc. (PRAX) Competitors
The following stocks are similar to Praxis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Praxis Precision Medicines Inc. (PRAX) Financial Data
Praxis Precision Medicines Inc. has a market capitalization of $8.77B with a P/E ratio of -23.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -35.3%.
Valuation Metrics
Market Cap
$8.77B
Enterprise Value
$8.27B
P/E Ratio
-23.3x
PEG Ratio
8.5x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+9.0%
Current Ratio
15.9x
Debt/Equity
0.1x
ROE
-35.3%
ROA
-23.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Praxis Precision Medicines Inc. (PRAX) Business Model
About Praxis Precision Medicines Inc.
What They Do
Develops treatments for central nervous system disorders.
Business Model
Praxis Precision Medicines Inc. generates revenue by developing and commercializing innovative therapies aimed at treating various CNS disorders, including epilepsy and psychiatric conditions. The company focuses on addressing unmet medical needs by leveraging its research in genetics and neurobiology to create effective treatment options.
Additional Information
With a robust pipeline of therapeutic candidates, Praxis aims to improve patient outcomes and contribute to the advancement of personalized medicine. The company is positioned as an emerging leader in the biopharma sector, targeting a significant market of millions suffering from CNS disorders globally.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
168
CEO
Mr. Marcio Silva De'Souza M.B.A.
Country
United States
IPO Year
2020
Website
praxismedicines.comPraxis Precision Medicines Inc. (PRAX) Latest News & Analysis
Latest News
Quick Summary
Praxis Precision Medicines and Remagine Labs announced a collaboration to develop a transdermal delivery system for ulixacaltamide, potentially expanding its market and lifecycle management.
Why It Matters
The collaboration enhances ulixacaltamide's delivery method, potentially broadening its market and revenue opportunities, and indicates Praxis's commitment to advancing its product pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 days ago
Quick Summary
Praxis Precision Medicines granted 951 restricted stock units to five new non-executive employees on July 1, 2026, as part of its 2024 Inducement Plan, complying with Nasdaq rules.
Why It Matters
The issuance of restricted stock units indicates Praxis is attracting talent, which could enhance its operational capabilities and drive future growth, impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Praxis Precision Medicines' NDA review for relutrigine has been extended by three months to December 27, 2026, due to a major amendment submitted to the FDA.
Why It Matters
The FDA's extension of the review period for Praxis's drug could impact timelines for potential revenue and market entry, affecting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Praxis Precision Medicines has a Strong Buy rating, with two NDAs accepted and PDUFA dates set for relutrigine (Sept 2026) and ulixacaltamide (Jan 2027). Breakthrough designation for elsunersen enhances its pipeline.
Why It Matters
Praxis Precision Medicines' Strong Buy rating reflects promising NDAs and catalysts in rare CNS disorders, indicating potential revenue growth and investment value through upcoming approvals and pipeline developments.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Praxis Precision Medicines (NASDAQ:PRAX) received FDA Breakthrough Therapy Designation for elsunersen (PRAX-222), targeting seizures linked to SCN2A-DEE.
Why It Matters
FDA's Breakthrough Therapy Designation for Praxis Precision Medicines' treatment could accelerate its development and market entry, enhancing potential revenue and stock value.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Praxis Precision Medicines received FDA Breakthrough Therapy Designation for elsunersen (PRAX-222) for treating SCN2A-DEE, showing a 77% reduction in seizures in trials.
Why It Matters
The Breakthrough Therapy Designation for elsunersen enhances Praxis Precision Medicines' credibility, potentially accelerating its market entry and increasing investor confidence in its pipeline and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PRAX Stock
What is Praxis Precision Medicines Inc.'s (PRAX) stock forecast for 2027?
Based on our analysis of 9 Wall Street analysts, Praxis Precision Medicines Inc. (PRAX) has a median price target of $562.50. The highest price target is $1,201.00 and the lowest is $162.00.
Is PRAX stock a good investment in 2027?
According to current analyst ratings, PRAX has 16 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $314.56. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRAX stock?
Wall Street analysts predict PRAX stock could reach $562.50 in the next 12 months. This represents a 78.8% increase from the current price of $314.56. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Praxis Precision Medicines Inc.'s business model?
Praxis Precision Medicines Inc. generates revenue by developing and commercializing innovative therapies aimed at treating various CNS disorders, including epilepsy and psychiatric conditions. The company focuses on addressing unmet medical needs by leveraging its research in genetics and neurobiology to create effective treatment options.
What is the highest forecasted price for PRAX Praxis Precision Medicines Inc.?
The highest price target for PRAX is $1,201.00 from at , which represents a 281.8% increase from the current price of $314.56.
What is the lowest forecasted price for PRAX Praxis Precision Medicines Inc.?
The lowest price target for PRAX is $162.00 from at , which represents a -48.5% decrease from the current price of $314.56.
What is the overall PRAX consensus from analysts for Praxis Precision Medicines Inc.?
The overall analyst consensus for PRAX is bullish. Out of 9 Wall Street analysts, 16 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $562.50.
How accurate are PRAX stock price projections?
Stock price projections, including those for Praxis Precision Medicines Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 3:33 AM UTC